PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC 50 value of 49 nM and 135 nM on rhesus and human M1 receptor , respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease In Vivo PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine Dosage: 3 mg/kg, 10 mg/kg, or 30 mg/kg Administration: Oral administration Result: Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT). Form:Solid IC50& Target:EC50: 49 nM (Rhesus M1 receptor) and 135 nM (Human M1 receptor)